Zhongke and MSKCC clinical research on reishi products
On the morning of July 16, 2019, Sino-Sci group and Memorial Sloan Kettering Cancer Center signed a contract on the "Clinical research cooperation of compound Ganoderma spore capsule" in New York City. The signing ceremony was attended by Mr. Wang Lian 'An, the President of Sino-Sci group, Dr. Mao Jun, director of MSK integrated medical center, and other executives related to this project from both sides.
This clinical trial carried out in United States is the very first time a Chinese Ganoderma Lucidum (Reishi mushroom) enterprise collaborating with a world-famous professional tumor research institute to explore the function of reishi products in anti-tumor clinical research. Hopefully it could set up a new model of cancer research for modernized Traditional Chinese medicine (TCM) and provide a new platform for development of new TCM in the future.
Memorial Sloan Kettering Cancer Center (MSKCC), founded in 1884, is the oldest and largest private Cancer Center in the world. As of 2017, MSKCC has been ranked as the top two tumor hospitals in the United States for 28 consecutive years by U. S. News. MSKCC is dedicated to the study of the pathogenesis of human tumors. Based at the Memorial Hospital, MSKCC focuses on translational research with the goal of applying research findings to the treatment of patients. Another focus of MSKCC’s research is cancer immunotherapy, which employs the body's immune system to fight cancer cells. Today, MSK is among the 47 comprehensive cancer centers designated by the National Cancer Institute (NCI) for its scientific, clinical, and therapeutic excellence.